Top Section/Ad
Top Section/Ad
Most recent
US drug maker's stake in Haleon set to fall to 24%
Risk appetite is back and more deals coming, though one bad IPO would damage confidence in the recovery
More companies are getting ratings to woo bond investors
Europe's biggest IPO of the year so far gains traction with investors
More articles/Ad
More articles/Ad
More articles
-
After the listings in February delivered, Galderma adds fuel to the European IPO recovery
-
Long delayed listing of Nestlé's former skincare division is finally underway
-
LivaNova and MicroStrategy ride US tech convertible wave as maturity wall pushes issuers to refinance
-
Bankers hopeful more supply will follow, but no pipeline forthcoming
-
The strong market conditions are tempting cash rich issuers
-
Three borrowers head to euros to fund M&A activity